Eargo (EAR) 12-1 Month Momentum % : -62.81% (As of May. 03, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Eargo 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-03), Eargo's 12-1 Month Momentum % is -62.81%.

The industry rank for Eargo's 12-1 Month Momentum % or its related term are showing as below:

EAR's 12-1 Month Momentum % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -18.495 vs EAR: -62.81

Competitive Comparison of Eargo's 12-1 Month Momentum %

For the Medical Devices subindustry, Eargo's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eargo's 12-1 Month Momentum % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Eargo's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Eargo's 12-1 Month Momentum % falls into.

Eargo (NAS:EAR) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eargo (NAS:EAR) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Eargo 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Eargo's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Eargo (EAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Eargo Inc (NAS:EAR) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2665 North First Street, Suite 300, San Jose, CA, USA, 95134

Website

https://www.eargo.com

Eargo Inc is a medical device company, focused on improving the quality of life of people with hearing loss. The company offers hearing aids, professional support services, and other insurance-related services through a direct-to-consumer format with a personalized, consumer-centric approach. The product portfolio includes Eargo Neo HiFi, Eargo 5, Eargo 6, Eargo 7, and related accessories.

Executives

Mark Thorpe	officer: Chief Accounting Officer	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
William Brownie	officer: Chief Operating Officer	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Adam Laponis	officer: Chief Financial Officer	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Christian Gormsen	director, officer: President and CEO	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Trit Garg	director	C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Afshin Justin Sabet-peyman	director	C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Onkarr Narula	director	C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Donald J Spence	director	C/O OAKMONT ACQUISITION CORP., 33 BLOOMFIELD HILLS PARKWAY, SUITE 240, BLOOMFIELD HILLS MI 48304
Psc Echo Gp, Llc	10 percent owner	2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Psc Echo, Lp	10 percent owner	2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
David James Wu	director	411 FIRST AVENUE SOUTH, SUITE 600, SEATTLE WA 98104
Nina Richardson	director	C/O SILICON LABORATORIES, 400 W CESAR CHAVEZ, AUSTIN TX 78701
Katie J Bayne	director	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Geoff Pardo	director	26 TECHNOLOGY DRIVE, IRVINE CA 92618
Gilde Healthcare Holding B.v.	10 percent owner	NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB